Women, particularly women of color, remain underrepresented in antiretroviral (ARV) clinical
trials. To evaluate sex-based differences in darunavir/ritonavir-based therapy, the Gender, Race And Clinical
Experience (GRACE) study was designed to enroll and retain a high proportion of women representative of the
racial/ethnic demographics of women with HIV/AIDS in the United States. The recruitment and retention
strategies used in GRACE are described in this article.